Next-generation IgG protease candidate Xork to be licensed for development with AT845, an investigational Astellas Gene Therapies' product, for the treatment of Pompe Disease
Selecta to receive a $10M upfront payment and eligible to receive up to $340M for certain additional development and commercial milestones plus royalties on commercial sales
https://finance.yahoo.com/news/selecta-biosciences-astellas-announce-exclusive-123000572.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.